FDA's Pazdur expresses concerns over the hindrance caused to other sponsors' applications due to fighting accelerated approval withdrawal. US accelerated approvals face criticism at AACR24. Congressional authorities struggle with drug companies over accelerated approval withdrawal, leading to FDA time constraints. FDA considers adding another myeloma endpoint for accelerated approvals, affecting timely access. FDA's Pazdur criticizes sponsor-driven Adcomm open public hearings, emphasizing the need for confidence in the system.